开发列线图整合分子检测与临床变量以改善细胞学不确定甲状腺结节的恶性风险评估
这项前瞻性观察研究纳入1024个连续细胞学不确定甲状腺结节(ITNs),其中332例手术且有完整数据者进入模型。多变量逻辑回归模型交叉验证AUC为0.831(95%CI 0.787-0.874),整合分子检测与临床变量可改善ITNs恶性风险预测。
要点
- 高危突变或恶性分子标志物者恶性比值比为152.79(对照为突变阴性或良性分子标志物)。
- 最大结节尺寸>5 cm者恶性比值比为4.34(对照0-2 cm),核异型性增加4.26倍,超声恶性风险5类较1-3类增加2.89倍,触诊发现增加1.83倍。
- 低风险(0-30%)和中风险(31-70%)组最常见腺叶切除(分别为61%和70%),高风险(>70%)组全甲状腺切除为主(62%)。
核心结论
- 尽管分子检测本身在研究人群中对于监测与手术的决策起重要作用,但将分子检测结果与额外临床变量整合可改善ITNs的恶性风险预测。
- 作者认为结果强调在整合的多学科甲状腺结节诊断路径中结合分子检测结果的重要性。
研究设计与样本
- 前瞻性观察研究纳入2020年7月30日至2023年10月30日期间接受反射性ThyroSPEC分子检测的1024个连续细胞学不确定甲状腺结节(ITNs)。
- 多变量逻辑回归模型评估组织学结局与临床变量(触诊发现、超声风险分类、最大结节尺寸、Bethesda分类、Bethesda异型性、ThyroSPEC分类)的关系。
- 1024例中332例接受手术且所有变量数据完整者纳入模型,并基于模型开发列线图。
主要发现
- 模型交叉验证AUC为0.831(95%CI 0.787-0.874)。
- 高危突变或恶性分子标志物者恶性比值比为152.79(对照为突变阴性或良性分子标志物)。
- 最大结节尺寸>5 cm者恶性比值比为4.34(对照0-2 cm),核异型性存在增加恶性比值比4.26倍,超声恶性风险5类较1-3类增加2.89倍,触诊阳性发现增加1.83倍。
- 回归模型估计的整合恶性风险与手术类型显著相关(p < 0.001)。
- 低风险(0-30%)和中风险(31-70%)组最常见为腺叶切除(分别为61%和70%),高风险(>70%)组全甲状腺切除为主(62%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The introduction of molecular testing (MT) of cytologically indeterminate thyroid nodules (ITNs) alone has not impacted thyroidectomy rates. Due to this, we evaluated the incremental diagnostic value of various clinical variables in addition to MT results, in predicting the risk of malignancy (ROM) among ITNs. Methods: This prospective observational study included 1024 consecutive ITNs that underwent reflexive ThyroSPEC MT between Jul 30, 2020, and Oct 30, 2023. A multivariable logistic regression model was built to assess the relationship between histology outcomes and clinical variables, including nodule discovery by palpation, ultrasound risk categories, maximum nodule size, Bethesda category, Bethesda atypia, and ThyroSPEC categories. A total of 332 out of 1024 patients who underwent surgery and had complete data for all variables were included in the model. A nomogram was subsequently developed based on the model. Results: The model achieved a cross-validated AUC of 0.831 (95% confidence intervals: 0.787-0.874). Patients with high-risk mutations or malignant molecular markers exhibited significantly higher odds (152.79 times) of malignancy compared to those with mutation-negative or benign molecular marker results. Patients with maximum nodule size >5 cm have 4.34 times higher odds of malignancy than those 0-2 cm. The presence of nuclear atypia increased the odds of malignancy by 4.26 times, while ultrasound malignancy risk category 5 increased the odds of malignancy by 2.89 times compared to categories 1-3. Positive palpation discovery increased the odds by 1.83 times. The integrated ROM estimated from the regression model is significantly associated with the surgery type (p < 0.001). In the low (0-30%) and intermediate ROM (31-70%) categories, lobectomy alone is the most common surgery (61% and 70%, respectively), while in the high ROM (>70%) category, total thyroidectomy dominates (62%). Conclusions: Although MT alone played an important role in decision-making regarding surveillance versus surgery in our study population, integrating MT results with additional clinical variables improved the malignancy risk prediction for ITNs. Our results highlight the importance of contextualizing MT results within an integrated interdisciplinary thyroid nodule diagnostic pathway.
引用
- Wu J, Stewardson P, Eszlinger M, et al. Development of a Nomogram to Integrate Molecular Testing and Clinical Variables to Improve Malignancy Risk Assessment Among Cytologically Indeterminate Thyroid Nodules. Thyroid. 2025. PMID: 40040545. doi:10.1089/thy.2024.0481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。